UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

      X    QUARTERLY REPORT  UNDER TO SECTION 13 OR 15(d) OF THE   SECURITIES
           EXCHANGE ACT OF 1934

                 For the quarterly period ended March 31, 2005


           _ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934
                        For the transition period from to
                        Commission File Number 000-24541

                          CORGENIX MEDICAL CORPORATION
                 (Name of Small Business Issuer in its Charter)

              Nevada                           93-1223466
  (State or other jurisdiction of    (I.R.S. Employer Identification
  incorporation or organization)                  No.)


                12061 Tejon Street, Westminster, Colorado 80234

         (Address of principal executive offices, including zip code)

                                 (303) 457-4345


               (Issuer's telephone number, including area code)


      (Former  name,  former  address and former  fiscal year, if changed since
      last report)


Check  whether  the  issuer:  (1) filed  all  reports  required  to be filed by
Section  13 or 15(d) of the  Exchange  Act  during  the past 12 months  (or for
such shorter  period that the  registrant  was required to file such  reports),
and  (2)  has  been  subject  to  such  filing  requirements  for  the  past 90
days.     Yes X   No  ___
              -


The number of shares of Common Stock outstanding was 5,346,964 as of May 11,
2005.


Transitional Small Business Disclosure Format.     Yes _     No   X
                                                                  -

<PAGE>



2
                          CORGENIX MEDICAL CORPORATION


                                 March 31, 2005





                                TABLE OF CONTENTS


                                                                         Page


                                     Part I


                              Financial Information


      Item 1.   Consolidated Financial Statements                          3

      Item 2.   Management's Discussion and Analysis or Plan of Operation 13

      Item 3.  Controls and Procedures                                    17




                                     Part II


                                Other Information


      Item 1.   Legal Proceedings                                         22


      Item 2.   Changes in Securities and Use of Proceeds                 22


      Item 3.   Defaults Upon Senior Securities                           22


      Item 4.   Submission of Matters to a Vote of Security Holders       22


      Item 5.   Other Information                                         22


      Item 6.   Exhibits and Reports on Form 8-K                          22


      Certifications                                                      25


      Signature Page                                                      29




<PAGE>



                                     PART I
                   Item 1. Consolidated Financial Statements
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
                           Consolidated Balance Sheets

-------------------------------------------------------------------------------


                                                  March          June
                                                31, 2005       30, 2004
                                                (Unaudited)      ***
                     Assets

Current Assets:
   Cash and equivalents                       $  353,405       $ 468,954
   Accounts receivable, less allowance for
    doubtful accounts of  $30,410 and $13,410    817,134         834,153
   Inventories                                 1,163,548         982,227
   Prepaid expenses                               46,537          30,276
                                          -----------------   ----------------
                    Total current assets       2,380,624       2,315,610

Equipment:
   Capitalized software costs                    122,855         122,855
   Machinery and laboratory equipment            639,152         588,219
   Furniture, fixtures, leaseholds and office    521,406         511,488
equipment                                 ------------------ ------------------
                                               1,283,413       1,222,562
   Accumulated depreciation and amortization    (999,927)       (913,020)
                                          ------------------ ------------------
                    Net equipment                283,486         309,542
                                          ------------------ ------------------
Intangible assets:
   Licenses                                       18,275            -
   Patents, net of accumulated amortization of    42,198          98,070
    $1,075,346 and $1,019,474
   Goodwill                                       13,677          13,677
                                          ------------------ ------------------
                     Net intangible assets        74,150         111,747
                                          ------------------ ------------------
   Due from officer                               12,000          12,000
   Other assets                                   92,775          98,925
                                          ------------------ ------------------
                     Total assets         $    2,843,035       2,847,824

      Liabilities and Stockholders' Equity

Current liabilities:
   Current portion of notes payable       $      696,020        569,988
   Current portion of capital lease obligations   36,895         51,395

   Accounts payable                              603,006        483,642
   Accrued payroll and related liabilities       180,645        173,392

   Accrued interest                              154,509        127,831
   Accrued liabilities                           147,859        169,929
                                          ------------------ ------------------
                    Total current liabilities  1,818,934      1,576,177

Notes payable, excluding current portion         181,165        238,445

Capital lease obligations, excluding current      26,590          9,712
portion                                   ------------------ ------------------
                    Total liabilities          2,026,689      1,824,334

Redeemable common stock, 880,282 shares issued and outstanding at March 31,
   2005, aggregate redemption value of $500,000, net of
   unaccreted discount and issuance costs of  $0
   and $64,919                                   500,000        435,081

Stockholders' equity:
   Preferred stock, $0.001 par value.
   Authorized 5,000,000 shares, none issued or       -             -
   outstanding

   Common stock, $0.001 par value.  Authorized
   40,000,000 shares; issued and outstanding
   5,343,826 and 5,321,319 shares at March 31
   and June 30, respectively                       4,463          4,440
   Additional paid-in-capital                  5,461,107      5,449,100
   Accumulated deficit                        (5,135,248)    (4,853,767)
   Accumulated other comprehensive income
    (loss)                                       (13,976)       (11,364)
                                           ----------------- ------------------
                   Total stockholders'equity     316,346        588,409

                   Total liabilities and
                   stockholders' equity        2,843,035      2,847,824
                                           ================== =================
See accompanying notes to consolidated financial statements.
*** Derived from the audited financial statements for the year ended June 30,
2004


<PAGE>


5
4
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
     Consolidated Statements of Operations and Comprehensive Income (Loss)

                                  Three Months Ended     Nine Months Ended
                              March 31,    March 31,   March 31,   March 31,
                               2005          2004        2005        2004
                              --------------------------------------------
                                   (Unaudited)               (Unaudited)
Net sales                   $1,444,553    $1,355,973  $4,024,195  $3,745,041
Cost of sales                  508,571       419,341   1,516,844   1,337,146
                              --------------------------------------------

          Gross profit         935,982       936,632   2,507,351   2,407,895


Operating expenses:
   Selling and marketing       360,758       327,612   1,105,234     981,705

   Research and development    146,918       193,254     442,363     563,482

   General and
administrative                 273,804       305,982     907,345     846,029
                            -------------------------------------------------
                            -------------------------------------------------
   Total expenses              781,480       826,848   2,454,942   2,391,216


      Operating income (loss)  154,502       109,784      52,409      16,679

Interest expense, net           78,827        21,395     268,971      69,190

                            -------------------------------------------------

          Net income (loss)     75,675        88,389    (216,562)    (52,511)


 Accretion of discount on
   redeemable common stock      21,641        21,639      64,919      64,917
                            ---------------------------------------------------
                            ---------------------------------------------------

Net income (loss)
 available to common
 stockholders                $ 54,034         $66,750  $(281,481)   $(117,428)
                             ==================================================

 Net income (loss) per
share, basic                    $0.01          $ 0.01    $(0.05)      $(0.02)

 Net income (loss) per
share, diluted                 $ 0.01          $0.01     $(0.05)      $(0.05)

Weighted average shares
   outstanding,             5,341,715      5,307,084  5,338,421     5,300,216
      Basic (note 2)

Weighted average shares
   outstanding,
   diluted (note 2)         5,367,863      5,971,572  5,338,421     5,300,216
                            =========      =========  =========     ===========
        Net income (loss)     $75,675        $88,389  $(216,562)     $(52,511)


Other comprehensive income
(loss)-foreign
currency translation            2,734         (9,322)    (2,612)      (9,759)
                           ----------      ----------   --------     ----------
 Total comprehensive
 income (loss)                 $78,409       $79,067  $(219,174)     $(62,270)
                            ==========      =========  =========     ==========
See accompanying notes to consolidated financial statements.



<PAGE>


                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
                 Consolidated Statement of Stockholders' Equity
                    For the nine months ended March 31, 2005

            Common   Common                          Accumulated
            Stock,   Stock,   Additional                other          Total
            Number   $0.001    paid-in   Accumulated comprehensive stockholders'
          of shares   par     capital      Deficit      income        equity


Balance at
June 30,
2004      5,321,319  $4,440  $5,449,100 $(4,853,767)  $(11,364)      $588,409


Issuance of
common stock
and stock
options for
services     22,507     23       12,007                               12,030

Foreign currency translation                            (2,612)       (2,612)

Accretion of
discount on
redeemable
common stock                              (64,919)                   (64,919)
Net loss                                 (216,562)                  (216,562)
                                         ---------                  ---------
                  -------------------------------------------------------------
                  -------------------------------------------------------------

Balance at
March 31
2005       5,343,826 $4,463   $5,461,107 $(5,135,248)  $(13,976)    $316,346
           ========= ======    ========= ============  =========    ========



<PAGE>




                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES



                      Consolidated Statements of Cash Flows
-------------------------------------------------------------------------------

                                                     Nine Months Ended
                                                 March 31,        March 31,
                                                   2005              2004
                                               -------------------------------
                                                         (Unaudited)
Cash flows from operating activities:
  Net loss                                     $(216,562)        $(52,511)
  Adjustments to reconcile net income
 (loss) to net cash provided by
        (used in) operating activities:
          Depreciation and amortization          141,972          148,041
          Accretion of discount on
          notes payable                          204,315            -
          Equity instruments issued
          for services                            12,030           10,643
          Changes in operating assets and
          liabilities:
               Accounts receivable                28,184         (112,351)
               Inventories                      (180,400)        (108,804)
               Prepaid expenses and
                 other assets                    (27,845)         (22,059)
               Accounts payable                  101,653         (183,315)
               Accrued payroll and
                 related liabilities              10,949           18,644
               Accrued interest and
                other liabilities                    397            7,803
                                               --------------------------------

                  Net cash provided by
                  (used in) operating
                  activities                     74,693          (293,909)
                                               --------------------------------

Cash flows used in investing activities:
   Purchases of equipment                       (14,229)           (3,370)
                                               --------------------------------

Cash flows from financing activities:
Proceeds from issuance of common
  stock, redeemable common stock,
  warrants and exercise of stock
  options                                          -                 5,990

Proceeds from issuance of notes
  payable                                          -                666,031
Payments on notes payable                       (135,562)          (159,295)
  Payments on capital lease obligations          (43,021)           (72,064)
  Payments for costs of issuance of
    common stock                                   -                    (22)
                                               -------------------------------

         Net cash (used in) provided by
         financing activities                   (178,583)           440,640
                                               -------------------------------

         Net increase (decrease) in
         cash and cash equivalents              (118,119)           143,361


Impact of foreign currency translation
 adjustment on cash                                 2,570              2,695

Cash and cash equivalents at beginning
 of period                                        468,954            342,406
                                               --------------------------------
Cash and cash equivalents at end of
 period                                         $ 353,405          $ 488,462
                                               ================================

Supplemental cash flow disclosures:

   Cash paid for interest                      $   40,358          $ 49,089
                                               -------------       ------------
Noncash investing and financing
activity--
    Equipment acquired under capital leases    $   45,400                  -
                                              --------------       ------------

See accompanying notes to consolidated financial statements.


<PAGE>


                 CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


1.    DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

      Corgenix Medical Corporation (which we refer to as Corgenix or the
  Company) is engaged in the research, development, manufacture, and marketing
  of in vitro (outside the body) diagnostic products for use in disease
  detection and prevention. The Company currently sells 73 diagnostic products
  (the "Diagnostic Products") on a worldwide basis to hospitals, clinical
  laboratories, commercial reference laboratories, and research institutions.

      The Company's corporate headquarters is located in Westminster, Colorado.
  Corgenix has two wholly owned operating subsidiaries:

o     Corgenix, Inc., established in 1990 and located in Westminster,
           Colorado. Corgenix, Inc. is responsible for sales and marketing
           activities for North America and Japan, and also conducts product
           development, product support, regulatory affairs and product
           manufacturing of the Diagnostic Products.

o          Corgenix (UK) Ltd., is located in Peterborough, England. Corgenix UK
           manages the Diagnostic Business' international sales and marketing
           activities except for distribution in North America and Japan which
           is under the responsibility of Corgenix, Inc.

      On October 15, 2004 the Company and Genesis Bioventures, Inc. (which we
  refer to as GBI or Genesis) a biomedical development company focused on the
  development of diagnostic tests signed an amendment to the May 21, 2004
  Amended and Restated Plan of Merger (the "Merger Agreement"), extending the
  closing date for the proposed merger to on or before February 28, 2005. The
  extension was executed in the form of Amendment No. 1 (the "Amendment") to the
  Merger Agreement, a copy of which was filed on Form 8-K on October 20, 2004.

      The Amendment, among other changes, allowed the Company to terminate the
  Merger Agreement at any time prior to November 30, 2004 if it were not
  satisfied with the terms or the progress of the new equity financing. A new
  equity financing in an amount of at least $6,000,000 was a condition to the
  closing of the Merger pursuant to section 9.13 of the Merger Agreement. On
  November 30, 2004, the Company and Genesis agreed to extend the date for
  obtaining the financing to December 10, 2004. On December 9, 2004, the parties
  agreed to extend the date to December 31, 2004, and on December 31, 2004, the
  parties agreed to extend the deadline for terminating the Merger Agreement to
  January 15, 2005. These extensions are documented as Amendments No. 2, 3 and 4
  to the Merger Agreement. Management of Corgenix believed that, given the
  delays experienced during the holiday season, and given the timing delays that
  are often associated with seeking funds in overseas markets, it was
  appropriate and in the best interests of the Company to allow Genesis
  additional time to pursue the new equity financing.

      On January 14, 2005 Corgenix terminated the Amended and Restated Agreement
  and Plan of Merger with Genesis Bioventures, Inc. due to the lack of progress
  towards the completion of the $6.0 million merger-related financing and the
  expiration of key dates within the Merger Agreement (as amended).

      On March 24, 2004, Genesis advanced $500,000 to Corgenix, which is
  represented by a promissory note ("Bridge Note"). As of March 31, 2005, the
  Company owed $470,000 on the Bridge Note. As a result of the termination of
  the Merger Agreement, the note will convert to a fixed two-year term note
  bearing interest at the prime rate in effect as of the date of termination of
  the Merger Agreement, or 5.25%. The note will be fully-amortized over four
  semi-annual payments of principal and accrued interest; however, the note is
  convertible, at the election of Genesis, into Corgenix common stock at a
  conversion price of $.568 per share.

      The market value of the Company's stock had increased from the date of the
  letter of intent to the date the Bridge Note was executed, resulting in a
  beneficial conversion feature that was credited to equity, and an equal amount
  is being recognized as interest expense over the term of the Bridge Note,
  using the effective interest method.
         The accompanying consolidated financial statements have been prepared
  without audit and in accordance with accounting principles generally accepted
  in the United States of America for interim financial information and with the
  instructions to Form 10-QSB and Article 10 of Regulation S-X. Accordingly,
  they do not include all of the information and footnotes required by
  accounting principles generally accepted in the United States of America for
  complete financial statements. In the opinion of the Company's management, the
  financial statements include all adjustments (consisting of normal recurring
  accruals and adjustments) required to present fairly the Company's financial
  position at March 31, 2005 and June 30, 2004 and the results of operations for
  each of the three and nine month periods ended March 31, 2005 and 2004, and
  the cash flows for each of the nine month periods then ended. The operating
  results for the three and nine months ended March 31, 2005 are not necessarily
  indicative of the results that may be expected for the year ended June 30,
  2005. For further information, refer to the consolidated financial statements
  and footnotes thereto included in the Company's annual report on Form 10-KSB
  for the fiscal year ended June 30, 2004.
      Management of the Company has made a number of estimates and assumptions
 relating to the reporting of assets and liabilities and the disclosure of
 contingent assets and liabilities to prepare these financial statements in
 conformity with accounting principles generally accepted in the United States
 of America. Significant assumptions inherent in the preparation of the
 accompanying financial statements include, but are not limited to, revenue
 recognition and allowances for doubtful accounts, the provision for excess and
 obsolete inventories, and commitments and contingencies. Actual results could
 differ from those estimates.

  2.     EARNINGS PER SHARE

      Basic earnings (loss) per share is computed by dividing net income (loss)
 available to common stockholders by the weighted average number of common
 shares outstanding. Diluted earnings (loss) per share is computed by dividing
 net income (loss) available to common stockholders by the weighted average
 number of common shares outstanding increased for the dilutive effect of
 potentially dilutive securities outstanding during the period. The dilutive
 effect of stock options, warrants and their equivalents is calculated using the
 treasury stock method. No stock options were granted in the most recent quarter
 or nine months ended March 31, 2005 or 2004. Options, warrants and the rights
 under convertible debt to purchase common stock totaling 1,252,820 shares for
 the quarter ended March 31, 2005, and totaling 917,350 shares for the quarter
 ended March 31, 2004 respectively, are not included in the calculation of
 weighted average common shares-diluted below as their effect is anti-dilutive.
 Redeemable common stock is included in the common shares outstanding for
 purposes of calculating net loss per share.

      The components of basic and diluted income (loss) per share are as
follows:
                              3 months  3 months    9 months  9 months
                                ended     ended      ended       ended
                              March 31, March 31,   March 31,  March 31,
                               2005        2004       2005        2004
                               ---------------------------------------
                               ---------------------------------------

Net  income  (loss)  available
to common stockholders         $54,034   66,750    (281,481)  (117,428)
                               ============================= =========

Common and common equivalent shares outstanding:
                               -------------------------------------------
   Weighted average common
   shares-basic              5,341,715  5,307,084    5,338,421 5,300,216
  Dilutive effect of
   potentially dilutive
   securities Outstanding       26,148    664,488         -         -
                               -------------------------------------------
                               -------------------------------------------
     Weighted average common
     shares-diluted          5,367,863  5,971,572     5,338,421 5,300,216
                             =========  =========     ========= =========
   Net income (loss) per
     share-basic            $     0.01  $    0.01     $   (0.05) $ (0.02)
                             ============================================
  Net income (loss) per $
     share-diluted          $     0.01  $    0.01     $   (0.05) $ (0.02)
                             ============================================


  3.    INCOME  TAXES

           A valuation allowance was provided for deferred tax assets, as the
  Company is unable to conclude under relevant accounting standards that it is
  more likely than not that deferred tax assets will be realizable.

4.      SEGMENT INFORMATION

      The Company has two segments of business: domestic and international
  operations. International operations primarily transact sales with customers
  in Europe and continents other than North America, while domestic operations
  transact sales primarily in North America. The following table sets forth
  selected financial data for these segments for the three and nine month
  periods ended March 31, 2005 and 2004.
              Three Months Ended March 31,          Nine Months Ended March 31,
          Domestic  International   Total    Domestic  International  Total

Net
sales
2005    $ 1,014,058    430,495    1,444,553  2,893,021   1,131,174  4,024,195
2004    $ 1,022,509    333,464    1,355,973  2,873,996     871,045  3,745,041
        ----------    --------    ---------  ---------   ----------- --------
        ==========    ========     ========  =========   ==========  ========
Net
income
(loss)
2005    $ (134,014)    209,689       75,675   (600,708)    384,146  (216,562)
2004    $  (5,965)      94,354       88,389   (252,468)    199,957  (52,511)
        ==========    ========       =======   =======    ========= ========
Depreciation
and
amortization
2005    $  47,363          576       47,939   140,263        1,709  141,972
2004    $  49,444          512       49,956   146,502        1,539  148,041
        ==========     ========     =======    =======    ========= ========

Interest    expense,
net
2005    $ 77,775         1,052       78,827   265,894        3,077   268,971
2004    $ 19,918         1,477       21,395    62,204        6,986    69,190
        ----------     --------      -------  -------     --------- --------
        ==========     ========      =======  =======     ========= ========
Segment                  4
assets
2005    $2,415,526      23,509    2,839,035  2,415,526     423,509  2,839,035
June 30,
2004    $ 2,411,152    412,133    2,823,285  2,411,152     412,133  2,823,285
        ==========     ========   =========  ==========   ========= ==========


5.    REDEEMABLE COMMON STOCK

    On July 1, 2002, the Company entered into an agreement ("MBL Agreement")
  with Medical & Biological Laboratories Co., Ltd. (MBL), a strategic partner
  and manufacturer of autoimmune diagnostic kits located in Nagoya, Japan under
  which the Company sold 880,282 shares, on a redeemable basis, of its $.001 par
  value common stock to MBL for gross proceeds of $500,000. Pursuant to the MBL
  Agreement, MBL can require the Company to repurchase at the same price in the
  event that a previously existing distribution agreement with RhiGene, Inc. is
  terminated or once it expires. For no additional consideration, MBL was also
  issued warrants to purchase an additional 880,282 shares of Common Stock at a
  price of $.568 per share, which is equal to an aggregate amount of $500,000.
  These warrants expire on July 3, 2007 and may be exercised in whole or in part
  at any time prior to their expiration. The estimated fair value of the warrant
  upon issuance was calculated as $401,809 using the Black-Scholes
  option-pricing model with the following assumptions: no expected dividend
  yield, 143% volatility, risk free interest rate of 4.2% and an expected life
  of five years. The gross proceeds of $500,000 were allocated $277,221 to
  redeemable common stock and $222,779 to the related warrants based on the
  relative fair values of the respective instruments to the fair value of the
  aggregate transaction. Issuance costs and the discount attributed to the
  redeemable common stock upon issuance were accreted over the 33-month period
  ended March 31, 2005 which was the first date on which the put option could be
  exercised, and the expiration date of the distribution agreement between the
  Company and RhiGene, Inc. Furthermore, pursuant to the agreement with MBL, as
  long as MBL holds at least 50% of the common stock purchased under the MBL
  agreement, MBL must give its written consent with respect to the payment of
  any dividend, the repurchase of any of the Company's equity securities, the
  liquidation or dissolution of the Company or the amendment of any provision of
  the Company's Articles of Incorporation or Bylaws which would adversely affect
  the rights of MBL under the stock purchase transaction documents. MBL was
  granted standard anti-dilution rights with respect to stock issuances not
  registered under the Securities Act. MBL also received standard piggyback
  registration rights along with certain demand registration rights. On March
  31, 2005 we signed a new distribution and OEM Supply Agreement with MBL
  International, Inc., (MBLI), a wholly owned subsidiary of MBL, which will
  grant us non-exclusive rights to distribute MBL's complete diagnostic line of
  autoimmune testing products in the United States and exclusive distribution
  rights to the OEM Label products worldwide excluding the United States, Japan,
  Korea, and Taiwan. In addition, Corgenix and MBL are negotiating a new stock
  redemption agreement with MBL wherein, in principle, one-half (440,141) of the
  original redeemable shares were converted into a three year note payable with
  interest at prime (6% as of May 5, 2005) plus two percent with payments
  commencing June 1, 2005. The remaining 440,181 shares will be redeemable by
  the Company at $.568 per share as of June 1, 2008 for any shares still owned
  at that time by MBL and only to the extent that MBL has not realized at least
  $250,000 in gross proceeds upon the sales of its redeemable shares in the open
  market for the time period June 1, 2005 through May 31, 2008. Finally, the
  warrants originally issued to MBL to purchase 880,282 shares are expected to
  be extended one year to July 3, 2008 and will be re-priced with respect to
  their exercise price.


   6.  STOCK PLANS

      The Company accounts for its stock plans in accordance with the provisions
 of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock
 Issued to Employees, SFAS No.148, Accounting for Stock-Based
 Compensation-Transition and Disclosure, and related interpretations. As such,
 compensation expense is recorded on the date of grant only if the current
 market price of the underlying stock exceeds the exercise price. SFAS No. 123,
 Accounting for Stock-Based Compensation, permits entities to recognize as
 expense over the vesting period the fair value of all stock-based awards on the
 date of grant. Alternatively, SFAS No. 123 also allows entities to continue to
 apply the provisions of APB Opinion No. 25 and provide pro forma net loss
 disclosures for employee stock option grants as if the fair-value-based method
 defined in SFAS No. 123 had been applied. The Company has elected to continue
 to apply the provisions of APB Opinion No. 25 and provide the pro forma
 disclosures required by SFAS No. 123.

      Had the Company determined compensation cost based on the fair value at
 the date of grant for its stock options under SFAS No. 123, the Company's net
 income would have been decreased or net loss would have been increased to the
 pro forma amounts indicated as follows:


                                  Three   Three    Nine     Nine
                                 Months   Months   Months   Months
                                  Ended   Ended    Ended    Ended
                                 -----------------------------------
                             March 31, March 31,  March 31, March 31,
                             ---------------------------------------
                               2005     2004        2005     2004
                             ---------------------------------------

  Net      income      (loss)
    available    to    common
    stockholders as reported  $54,034  66,750   $(281,481) $(117,428)
  Deduct  total   stock-based
    employee     compensation
    expense  determined under
    fair-value   method   for
    all awards, net of tax    (10,679)(15,107)    (32,037)   (45,321)
                              ---------------------------------------
                              ---------------------------------------
  Net income (loss)
   available    to    common
   stockholders pro forma    $ 43,355 $51,643   $(313,518)  $(162,749)
                             =========================================
  Net income (loss) per
    share as reported           $0.01   $0.01     $(0.06)     $(0.02)
  Net income (loss) per
    share pro forma             $0.01   $0.01     $(0.06)     $(0.03)

    Fair value was determined using the Black Scholes option - pricing model.
    There were no stock options granted during the nine months ended March 31,
    2005 and 2004.

<page>
    7.  NOTES PAYABLE

    Certain of the notes payable restrict the payment of dividends on the
    Company's common stock. Notes payable consist of the following at March 31,
    2005 and June 30, 2004:

                                                 March 31,     June 30,
                                                   2005         2004
                                              ------------  ------------

    Bridge Note payable to
    Genesis Bioventures, Inc., net of            $259,116      $84,801
    discount of $210,884 and  $415,199.
    See discussion of terms below.

    Note payable to a bank, with interest at prime plus 2.75%
    (7.0% at June 30, 2004), due in monthly installments of principal and
    interest of $13,369 through January 2007, collateralized by commercial
    security agreements and a key man
    life insurance policy.                        266,174      369,351

    Variable Rate Loan payable to a bank, with interest at prime plus
    1.0% (minimum rate of 5.5%), due in monthly installments of principal and
    interest through January 2005. This loan payable is collateralized by
    accounts receivable and is an extension and conversion of a revolving credit
    agreement with the same bank which matured on March 31,
    2004. *
                                                   291,121      292,507

    Notes payable, unsecured, to former preferred stockholders,
    with interest at 17%, due on demand. At March 31, 2005 and June 30, 2004,
    the Company was in default on these notes.
                                                    60,774       61,774
                                                -----------  ------------
                                                   877,185       808,433

    Less current portion                          (696,020)     (569,988)
                                                -----------  ------------
          Notes payable, excluding
                current portion                   $181,165      $238,445
                                                ===========  ============
    * The variable note payable to a bank was due in full at January 31, 2005.
    The Company has not repaid the loan and has informed the Bank of the status
    of its current institutional financing. No demand for repayment has been
    made. It is the intention of the Company to pay the note in full with the
    proceeds from the current institutional financing, or alternatively to
    attempt to convert this loan to a term loan with a due date of three to five
    years. There is no assurance that the current institutional financing will
    be successful or, in the alternative, that the bank will agree to such terms
    in which case a near-term infusion of capital will be necessary to satisfy
    this note. Since the Company needs additional financing to meet our debt
    requirements, there is no assurance that we will be able to obtain such
    financing on terms satisfactory to us, if at all. The effects on the
    financial statements of not obtaining suitable financing cannot be
    determined.

    Aggregate maturities of notes payable by year, net of discount amount of
    $210,884, as of March 31, 2005, are as follows:

Years ending June 30:
  2005                        $  379,626
  2006                           364,462
  2007                           343,981
                              -----------
                              -----------
                                1,088,069
 Less unaccreted discount on
    Bridge Note                   210,884
                              -----------
                              -----------
 Net maturities               $  877,185

    The carrying values of notes payable approximate fair value based on their
    terms and floating market based interest rates.

           As described in Note 1, on March 24, 2004, Genesis advanced $500,000
    to Corgenix, which is represented by the Bridge Note. As of March 31, 2005,
    the Company owed $470,000 on the Bridge Note. As a result of the termination
    of the Merger Agreement, the note has converted to a fixed two-year term
    note bearing interest at the prime rate in effect as of the date of
    termination of the Merger Agreement, or 5.25%. The note is fully-amortized
    over four semi-annual payments of principal and accrued interest, with the
    first payment expected to be due six months after the January 14, 2005
    merger termination date; however, the note is convertible, at the election
    of Genesis, into Corgenix common stock at a conversion price of $.568 per
    share. The market value of the Company's stock was in excess of the
    potential conversion price at the date the note was executed, resulting in a
    beneficial conversion feature of approximately $660,000. As required by
    Emerging Issues Task Force Bulletin 98-5, "Accounting for Convertible
    Securities with Beneficial Conversion Features of Contingently Adjustable
    Conversion Ratios" and 00-27, "Application of Issue 98-5 to Certain
    Convertible Instruments", the entire proceeds of the Bridge Note were
    credited to additional paid-in capital. The Bridge Note was recorded net of
    a $500,000 discount, which is being accreted to interest expense over the
    expected term of the Bridge Note, using the effective interest method.
<page>
                                   Item 2.




                          CORGENIX MEDICAL CORPORATION
                    Management's Discussion and Analysis of
                 Financial Condition and Results of Operations


      The following discussion should be read in conjunction with the
consolidated financial statements and accompanying notes included elsewhere
herein.


      General


      Since the Company's inception, we have been primarily involved in the
research, development, manufacturing and marketing/distribution of diagnostic
tests for sale to clinical laboratories. We currently market 73 products
covering autoimmune disorders, cardiovascular diseases, and liver disease. Our
products are sold in the United States, the UK and other countries through our
marketing and sales organization that include contract sales representatives,
internationally through an extensive distributor network, and to several
significant OEM partners.

      We manufacture products for inventory based upon expected sales demand,
shipping products to customers, usually within 24 hours of receipt of orders if
in stock. Accordingly, we do not usually operate with a customer order backlog.

      Except for the fiscal year ending June 30, 1997, we have experienced
annual revenue growth since our inception, primarily from sales of products and
contract revenues from strategic partners. Contract revenues consist of service
fees from research and development agreements with strategic partners.

      Beginning in fiscal year 1996, we began adding third-party OEM licensed
products to our diagnostic product line. Currently we sell 70 products licensed
from or manufactured by third party manufacturers. We expect to expand our
relationships with other companies in the future to gain access to additional
products.

      Although we have experienced growth in revenues every year since 1990,
except for 1997, there can be no assurance that, in the future, we will sustain
revenue growth, current revenue levels, or achieve or maintain profitability.
Our results of operations may fluctuate significantly from period-to-period as
the result of several factors, including: (i) whether and when new products are
successfully developed and introduced, (ii) market acceptance of current or new
products, (iii) seasonal customer demand, (iv) whether and when we receive
research and development payments from strategic partners, (v) changes in
reimbursement policies for the products that we sell, (vi) competitive pressures
on average selling prices for the products that we sell, and (vii) changes in
the mix of products that we sell.

      Critical Accounting Policies

      The Company's consolidated financial statements are prepared in accordance
with accounting principles generally accepted in the United States ("GAAP") and
our significant accounting policies are summarized in Note 1 to the accompanying
consolidated financial statements. The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that
affect reported amounts of assets, liabilities, disclosure of contingent assets
and liabilities at the date of the financial statements and reported amounts of
revenues and expenses during the reporting period. Actual results could differ
significantly from those estimates.

      The Company maintains an allowance for doubtful accounts based on its
historical experience and provides for any specific collection issues that are
identified. Such allowances have historically been adequate to provide for our
doubtful accounts but involve a significant degree of management judgment and
estimation. Worse than expected future economic conditions, unknown customer
credit problems and other factors may require additional allowances for doubtful
accounts to be provided for in future periods. Equipment and software are
recorded at cost. Equipment under capital leases is recorded initially at the
present value of the minimum lease payments. Depreciation and amortization is
calculated primarily using the straight-line method over the estimated useful
lives of the respective assets that range from 3 to 7 years. The internal and
external costs of developing and enhancing software costs related to website
development, other than initial design and other costs incurred during the
preliminary project stage, are capitalized until the software has been
completed. Such capitalized amounts began to be amortized commencing when the
website was placed in service on a straight-line basis over a three-year period.
When assets are sold, retired or otherwise disposed of, the cost and related
accumulated depreciation are eliminated from the accounts and a gain or loss is
recognized. Repair and maintenance costs are expensed as incurred. We evaluate
the realizability of our long-lived assets, including property and equipment,
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. Revenue from sale of products is recognized
upon shipment of products. Revenue from research and development contracts
represents amounts earned pursuant to agreements to perform research and
development activities for third parties and is recognized as earned under the
respective agreement. Because research and development services are provided
evenly over the contract period, revenue is recognized ratably over the contract
period. Research and development agreements in effect in 2004 and 2003 provided
for fees to the Company based on time and materials in exchange for performing
specified research and development functions. Research and development and
advertising costs are expensed when incurred. Inventories are recorded at the
lower of cost or market, using the first-in, first-out method.


      Results of Operations


      Three Months Ended March 31, 2005 compared to 2004

      Net sales. Net sales for the quarter ended March 31, 2005 were
approximately $1,445,000, a 6.6% increase from approximately $1,356,000 for the
quarter ended March 31, 2004. Domestic sales decreased 0.8% while sales to
international distributors increased 29.1% from year to year. With respect to
the Company's major product lines, Phospholipids kit sales decreased 2.1% for
the fiscal quarter, Coagulation kit sales decreased 1.5 %, HA kit sales
increased 52.8%, primarily due to the timing of orders, and Autoimmune kit sales
increased 102.7%. Additionally, OEM sales decreased 27.9%. Sales of products
manufactured for us by other companies while still relatively small, are
expected to continue to increase during fiscal 2005.

      Cost of sales. Cost of sales, as a percentage of sales, increased to 35.2%
in the quarter ended March 31, 2005 from 30.9% in 2004 primarily due to higher
raw material costs associated with the new manufacturing format of the Company's
main product line and the purchase of certain raw materials which were formerly
manufactured in-house.

      Selling and marketing. Selling and marketing expenses increased 10.1% to
approximately $361,000 in the quarter ended March 31, 2005 from approximately
$328,000 in 2004. The majority of this increase involved increases in royalties,
labor-related costs and other promotion related expenses.

      Research and development. Research and development expenses decreased
23.8% to approximately 147,000 in the quarter ended March 31, 2005 from
approximately $193,000 for the quarter ended March 31, 2004. The majority of
this decrease involved reductions in labor-related costs, consulting and
laboratory supplies resulting from recently ended development projects and
head-count reductions.

      General and administrative. General and administrative expenses decreased
approximately $32,000 or 10.5% to approximately $274,000 in the quarter ended
March 31, 2005 from approximately $306,000 for the quarter ended March 31, 2004,
primarily due to decreases in merger-related expenses, outside services, and
equipment lease expense.

    Interest expense. As mentioned in the Notes to Consolidated Financial
Statements, the market value of the Company's stock had increased from the date
of the letter of intent to the date the Bridge Note was executed, resulting in a
beneficial conversion feature that was credited to equity, and an equal amount
is being recognized as interest expense over the potential term of the Bridge
Note, using the effective interest method. Interest expense increased 276.2% to
approximately $79,000 in the quarter ended March 31, 2005 from approximately
$21,000 for the quarter ended March 31, 2004 due primarily to the accretion of
discount on the Bridge Note payable to Genesis.

      Accretion of discount on redeemable common stock. This item represents the
accretion of the discount on redeemable common stock over the 33 month period
from the date the stock was issued to the presently expected first date on which
the related embedded put option may be exercised (March 31, 2005). The
redeemable common stock was issued in July 2002.

      Nine Months Ended March 31, 2005 compared to 2004

      Net sales Net sales for the nine months ended March 31, 2005 were
approximately $4,024,000, a 7.4% increase from approximately $3,745,000 for the
nine months ended March 31, 2004. Domestic sales increased .6% while sales to
international distributors increased 29.9% from year to year. With respect to
the Company's major product lines, Phospholipids kit sales increased 0.9% for
the current six month period, Coagulation kit sales increased 19.9 %, HA kit
sales increased 33.6%, and Autoimmune kit sales increased 81.6%. Additionally,
OEM sales decreased 9.7%. Sales of products manufactured for us by other
companies while still relatively small, are expected to continue to increase
during fiscal 2005.

      Cost of sales. Cost of sales, as a percentage of sales, increased to 37.7%
in the nine months ended March 31, 2005 from 35.7% in 2004 primarily due to
higher raw material costs associated with the new manufacturing format of the
Company's main product line, the purchase of certain raw materials which were
formerly manufactured in-house.

      Selling and marketing. Selling and marketing expenses increased 12.6% to
approximately $1,105,000 in the nine months ended March 31, 2005 from
approximately $982,000 in 2003. The majority of this increase involved increases
in royalties, labor-related costs and other promotion related expenses.

      Research and development. Research and development expenses decreased
21.5% to approximately $442,000 in the nine months ended March 31, 2005 from
approximately $563,000 for the nine months ended March 31, 2004. The majority of
this decrease involved reductions in labor-related costs, consulting and
laboratory supplies resulting from recently ended development projects and
head-count reductions.

      General and administrative. General and administrative expenses increased
approximately $61,000 or 7.2% to approximately $907,000 in the nine months ended
March 31, 2005 from approximately $846,000 for the nine months ended March 31,
2004, primarily due to increases in merger-related expenses, outside services
and legal expense.

      Interest expense. Interest expense increased 289.9% to approximately
$269,000 in the nine months ended March 31, 2005 from approximately $69,000 for
the nine months ended March 31, 2004 due primarily to the accretion of discount
on the Bridge Note payable to Genesis.

      Liquidity and Capital Resources

      The Company has $353,405 of cash at March 31, 2005 compared to $255,223 at
March 31, 2004 and has not repaid a loan of $291,121 due on January 31, 2005.
Cash provided by operating activities was $74,693 for the nine months ended
March 31, 2005 compared to cash used in operating activities of $293,909 during
the prior year's comparable period. This change compared to the year earlier
period resulted primarily from an increase in operating income and an increase
in accounts payable partially offset by an increase in inventories. The Company
believes that uncollectible accounts receivable will not have a significant
effect on future liquidity, as a significant portion of its accounts receivable
are due from financially sound enterprises.

      Net cash used in investing activities, the purchase of equipment, was
$14,229 in the nine months ended March 31, 2005 compared to $3,370 for the year
earlier period. The increase was mainly attributable to increased spending on
refrigeration and manufacturing equipment and computers.

      Net cash used in financing activities amounted to $178,583 during the nine
months ended March 31, 2005 compared to cash provided by financing activities of
$440,640 for the year earlier period. This change compared to the year earlier
period was primarily due to a substantial decrease in the proceeds from notes
payable as a result of the Company's reduced borrowing capacity pursuant to
restrictions imposed by its existing bank loan agreements.

      Historically, we have financed our operations primarily through long-term
debt and by sales of common and preferred stock. Other than sales of stock to
our employees through our Employee Stock Purchase Plan, no common or preferred
stock was sold in the nine month periods ended March 31, 2005 or 2004.

      We have also financed operations through sales of diagnostic products and
agreements with strategic partners. Accounts receivable decreased 2% to $817,134
at March 31, 2005 from $834,153 at March 31, 2004 primarily as a result the
accelerated collection of certain accounts.

      Our future capital requirements will depend on a number of factors,
including the ability to complete new equity or debt financing, the possible
redemption of common stock, our profitability or lack thereof, the rate at which
we grow our business and our investment in proprietary research activities, the
ability of our current and future strategic partners to fund outside research
and development activities, our success in increasing sales of both existing and
new products and collaborations, expenses associated with unforeseen litigation,
regulatory changes, competition, technological developments, general economic
conditions and potential future merger and acquisition activity. Our principal
sources of liquidity have been, cash raised from the private sale of redeemable
common and common stock, the Bridge Note from Genesis, and long-term debt
financing. Since the Takeout Financing and the planned merger with Genesis did
not occur, and if we are required to repurchase our redeemable common stock or
repay our variable rate bank note, we will need to implement new expense
reductions and seek new debt agreements and/or sell additional equity securities
in fiscal year 2005 to generate additional operating capital, to develop the
markets and obtain the regulatory approvals for our products in the United
States, and to pursue all of our strategic objectives. As a result, the Company
announced in January 2005 the engagement of Ascendiant Securities for investment
banking services. Specifically, Ascendiant and the Company are in the midst of
pursuing an institutional private placement which, if consummated, will include
convertible debt and the Company's common or preferred stock. The variable note
payable to a bank was due in full at January 31, 2005. The Company has not
repaid the loan nor have we had any discussions with the bank since early
January. It is the intention of the Company to pay the note in full with the
proceeds from the current institutional financing, or alternatively to attempt
to convert this loan to a term loan with a due date of three to five years.
There is no assurance that the current institutional financing will be
successful, or in the alternative, that the bank will agree to such terms in
which case a near-term infusion of capital will be necessary to satisfy this
note. Since the Company needs additional financing to meet our debt
requirements, there is no assurance that we will be able to obtain such
financing on terms satisfactory to us, if at all. Alternatively, any additional
equity financing may be dilutive to existing stockholders, and debt financing,
if available, may include restrictive covenants. If adequate funds are not
available, we might be required to limit our research and development activities
or our selling, marketing and administrative activities any of which could have
a material adverse effect on the future of the business. We believe that our
current availability of cash, working capital, future proceeds from the issuance
of common or preferred stock and debt financing and expected cash flows from
operations resulting from, if necessary, further expense reductions, will be
adequate to meet our ongoing needs for at least the next twelve months.
Management believes that the successful completion of an equity or debt
financing, referred to above, will be necessary to meet the Company's expected
debt service. However, as stated above, additional financing cannot be assured.
The effects on the financial statements of not obtaining suitable financing
cannot be determined.

Certain of the notes payable restrict the payment of dividends on the Company's
common stock.



                                       Item 3.


                               Controls and Procedures

               Evaluation of disclosure controls and procedures. The Company,
under the supervision and with the participation of the Company's management,
including its Chief Executive Officer and Chief Financial Officer, carried out
an evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures (as defined in Rules 240.13a-14(c) and
15d-14(c) under the Securities Exchange Act of 1934 (the "Exchange Act") as of a
date within ninety days before the filing date of this quarterly report (the
"Evaluation Date"). Based upon this evaluation, the Chief Executive Officer and
Chief Financial Officer concluded that, as of the Evaluation Date, the Company's
disclosure controls and procedures were effective for the purposes of recording,
processing, summarizing and timely reporting information required to be
disclosed by the Company in the reports that it files under the Securities
Exchange Act of 1934 and that such information is accumulated and communicated
to the Company's management in order to allow timely decisions regarding
required disclosure.

              Changes in internal controls. There have been no significant
changes in the Company's internal controls or in other factors that could
significantly affect the Company's disclosure controls and procedures subsequent
to the Evaluation Date, nor were there any significant deficiencies or material
weaknesses in the Company's internal controls.

      Forward-Looking Statements and Risk Factors

      This 10-QSB includes statements that are not purely historical and are
"forward-looking statements" within the meaning of Section 21E of the Securities
Act of 1934, as amended, including statements regarding our expectations,
beliefs, intentions or strategies regarding the future. All statements other
than historical fact contained in this 10-QSB, including, without limitation,
statements regarding our planned merger with Genesis, the Takeout Financing,
future product developments, strategic partnership expectations, technological
developments, research and development programs and distribution plans, are
forward-looking statements. All forward-looking statements included in this
10-QSB are based on information available to us on the date hereof, and we
assume no obligation to update such forward-looking statements. Although we
believe that the assumptions and expectations reflected in such forward-looking
statements are reasonable, we can give no assurance that such expectations will
prove to have been correct or that we will take any actions that may presently
be planned.

      Certain factors that could cause actual results to differ materially from
those expected include the following:

      Merger-related charges were incurred.

      Corgenix estimates that, in pursuing the proposed merger with Genesis, the
company has thus far incurred approximately $100,000 in certain merger-related
expenses consisting of legal, accounting fees, valuation, and other related
charges. The foregoing amounts are preliminary estimates and the actual amounts
may be higher or lower. In addition, these merger-related expenses are, per
verbal agreement with Genesis, to be shared equally with Genesis and thus,
approximately half of said expenses would be reimbursed by Genesis or offset
against the Bridge Note. Corgenix and Genesis are currently discussing the
details of such expense sharing and the management of Corgenix expects that the
amounts due from Genesis will be offset against the amount due on the Bridge
Note.

      We continue to incur losses and the Company requires additional financing.

We have incurred operating losses and negative cash flow from operations for
most of our history. Losses incurred since our inception have aggregated
$5,135,248 and there can be no assurance that we will be able to generate
positive cash flows or raise the necessary capital to fund our operations in the
future or to pursue our strategic objectives. The variable note payable to a
bank was due in full at January 31, 2005. The Company has not repaid the loan
nor have we had any discussions with the bank since early January. It is the
intention of the Company to pay the note in full with the proceeds from the
current institutional financing, or alternatively to attempt to convert this
loan to a term loan with a due date of three to five years. There is no
assurance that the current institutional financing will be successful or, in the
alternative, that the bank will agree to such terms in which case a near-term
infusion of capital will be necessary to satisfy this note. We believe that our
current availability of cash, working capital, future proceeds from the issuance
of common or preferred stock and debt financing and expected cash flows from
operations resulting from, if necessary, further expense reductions, will be
adequate to meet our ongoing needs for at least the next twelve months. Since
the Company needs additional financing to meet our debt requirements, there is
no assurance that we will be able to obtain such financing on terms satisfactory
to us, if at all. Alternatively, any additional equity financing may be dilutive
to existing stockholders, and debt financing, if available, may include
restrictive covenants. If adequate funds are not available, we might be required
to limit our research and development activities or our selling, marketing and
administrative activities any of which could have a material adverse effect on
the future of the business. The effects of such actions on our financial
statements cannot be determined.

      We depend upon collaborative relationships and third parties for product
      development and commercialization.

      We have historically entered into research and development agreements with
collaborative partners, from which we derived revenues in past years. Pursuant
to these agreements, our collaborative partners have specific responsibilities
for the costs of development, promotion, regulatory approval and/or sale of our
products. We will continue to rely on future collaborative partners for the
development of products and technologies. There can be no assurance that we will
be able to negotiate such collaborative arrangements on acceptable terms, if at
all, or that current or future collaborative arrangements will be successful. To
the extent that we are not able to establish such arrangements, we could
experience increased capital requirements or be forced to undertake such
activities at our own expense. The amount and timing of resources that any of
these partners devotes to these activities will generally be based on progress
by us in our product development efforts. Collaborative arrangements may be
terminated by the partner upon prior notice without cause and there can be no
assurance that any of these partners will perform its contractual obligations or
that it will not terminate its agreement. With respect to any products
manufactured by third parties, there can be no assurance that any third-party
manufacturer will perform acceptably or that failures by third parties will not
delay clinical trials or the submission of products for regulatory approval or
impair our ability to deliver products on a timely basis.

      There can be no assurance of successful or timely development of
additional products.

      Our business strategy includes the development of additional diagnostic
products both for the diagnostic business and consumer products business. Our
success in developing new products will depend on our ability to achieve
scientific and technological advances and to translate these advances into
commercially competitive products on a timely basis. Development of new products
requires significant research, development and testing efforts. We have limited
resources to devote to the development of products and, consequently, a delay in
the development of one product or the use of resources for product development
efforts that prove unsuccessful may delay or jeopardize the development of other
products. Any delay in the development, introduction and marketing of future
products could result in such products being marketed at a time when their cost
and performance characteristics would not enable them to compete effectively in
their respective markets. If we are unable, for technological or other reasons,
to complete the development and introduction of any new product or if any new
product is not approved or cleared for marketing or does not achieve a
significant level of market acceptance, our results of operations could be
materially and adversely affected.

      Competition in the human medical diagnostics industry is, and is expected
      to remain, significant.

      Our competitors range from development stage diagnostics companies to
major domestic and international pharmaceutical companies. Many of these
companies have financial, technical, marketing, sales, manufacturing,
distribution and other resources significantly greater than ours. In addition,
many of these companies have name recognition, established positions in the
market and long standing relationships with customers and distributors.
Moreover, the diagnostics industry has recently experienced a period of
consolidation, during which many of the large domestic and international
pharmaceutical companies have been acquiring mid-sized diagnostics companies,
further increasing the concentration of resources. There can be no assurance
that technologies will not be introduced that could be directly competitive with
or superior to our technologies.



      Our products and activities are subject to regulation by various
      governments and government agencies.

      The testing, manufacture and sale of our products is subject to regulation
by numerous governmental authorities, principally the United States Food and
Drug Administration and certain foreign regulatory agencies. Pursuant to the
Federal Food, Drug, and Cosmetic Act, and the regulations promulgated there
under, the FDA regulates the preclinical and clinical testing, manufacture,
labeling, distribution and promotion of medical devices. We are not able to
commence marketing or commercial sales in the United States of new products
under development until we receive clearance from the FDA. The testing for,
preparation of and subsequent FDA regulatory review of required filings can be a
lengthy, expensive and uncertain process. Noncompliance with applicable
requirements can result in, among other consequences, fines, injunctions, civil
penalties, recall or seizure of products, repair, replacement or refund of the
cost of products, total or partial suspension of production, failure of the
government to grant premarket clearance or pre-market approval for devices,
withdrawal of marketing clearances or approvals, and criminal prosecution.

      There can be no assurance that we will be able to obtain necessary
regulatory approvals or clearances for our products on a timely basis, if at
all, and delays in receipt of or failure to receive such approvals or
clearances, the loss of previously received approvals or clearances, limitations
on intended use imposed as a condition of such approvals or clearances or
failure to comply with existing or future regulatory requirements could have a
material adverse effect on our business.

      As a manufacturer of medical devices for marketing in the United States,
we are required to adhere to applicable regulations setting forth detailed good
manufacturing practice requirements, which include testing, control and
documentation requirements. We must also comply with Medical Device Report (MDR)
requirements, which require that a manufacturer reports to the FDA any incident
in which its product may have caused or contributed to a death or serious
injury, or in which its product malfunctioned and, if the malfunction were to
recur, it would be likely to cause or contribute to a death or serious injury.
We are also subject to routine inspection by the FDA for compliance with Quality
System Regulations (QSR) requirements, MDR requirements and other applicable
regulations. Labeling and promotional activities are subject to scrutiny by the
FDA and, in certain circumstances, by the Federal Trade Commission. We may incur
significant costs to comply with laws and regulations in the future, which may
have a material adverse effect upon our business, financial conditions and
results of operations.

      Distribution of diagnostic products outside the United States is subject
to extensive government regulation. These regulations, including the
requirements for approvals or clearance to market, the time required for
regulatory review and the sanctions imposed for violations, vary from country to
country. We may be required to incur significant costs in obtaining or
maintaining foreign regulatory approvals. In addition, the export of certain of
our products that have not yet been cleared for domestic commercial distribution
may be subject to FDA export restrictions. Failure to obtain necessary
regulatory approval or the failure to comply with regulatory requirements could
have a material adverse effect on our business, financial condition and results
of operations.

      We depend upon distribution partners for sales of diagnostic products in
international markets.

      We have entered into distribution agreements with collaborative partners
in which we have granted distribution rights for certain of our products to
these partners within specific international geographic areas. Pursuant to these
agreements, our collaborative partners have certain responsibilities for market
development, promotion, and sales of the products. If any of these partners
fails to perform its contractual obligations or terminates its agreement, this
could have a material adverse effect on our business, financial condition and
results of operations.

      Third party reimbursement for purchases of our diagnostic products is
      uncertain.

      In the United States, health care providers that purchase diagnostic
products, such as hospitals and physicians, generally rely on third party
payers, principally private health insurance plans, federal Medicare and state
Medicaid, to reimburse all or part of the cost of the purchase. Third party
payers are increasingly scrutinizing and challenging the prices charged for
medical products and services and they can affect the pricing or the relative
attractiveness of the product. Decreases in reimbursement amounts for tests
performed using our diagnostic products, failure by physicians and other users
to obtain reimbursement from third party payers, or changes in government and
private third party payers' policies regarding reimbursement of tests utilizing
diagnostic products, may affect our ability to sell our diagnostic products
profitably. Market acceptance of our products in international markets is also
dependent, in part, upon the availability of reimbursement within prevailing
health care payment systems.

      Our success depends, in part, on our ability to obtain patents and license
      patent rights, to maintain trade secret protection and to operate without
      infringing on the proprietary rights of others.

      There can be no assurance that our issued patents will afford meaningful
protection against a competitor, or that patents issued to us will not be
infringed upon or designed around by others, or that others will not obtain
patents that we would need to license or design around. We could incur
substantial costs in defending the Company or our licensees in litigation
brought by others. Our business could be adversely affected.

      We may not be able to successfully implement our plans to acquire other
      companies or technologies.

      Our growth strategy may include the acquisition of complementary
companies, products or technologies. There is no assurance that we will be able
to identify appropriate companies or technologies to be acquired, to negotiate
satisfactory terms for such an acquisition, or to obtain sufficient capital to
make such acquisitions. Moreover, because of limited cash resources, we will be
unable to acquire any significant companies or technologies for cash and our
ability to effect acquisitions in exchange for our capital stock may depend upon
the market prices for our common stock. If we do complete one or more
acquisitions, a number of risks arise, such as short-term negative effects on
our reported operating results, diversion of management's attention,
unanticipated problems or legal liabilities, and difficulties in the integration
of potentially dissimilar operations. The occurrence of some or all of these
risks could have a material adverse effect on our business, financial condition
and results of operations.

      We depend on suppliers for our products' components.

      The components of our products include chemical and packaging supplies
that are generally available from several suppliers, except certain antibodies,
which we purchases from single suppliers. We mitigate the risk of a loss of
supply by maintaining a sufficient supply of such antibodies to ensure an
uninterrupted supply for at least three months. We have also qualified second
vendors for all critical raw materials and believe that we can substitute a new
supplier with respect to any of these components in a timely manner. There can
be no assurances that we will be able to substitute a new supplier in a timely
manner and failure to do so could have a material adverse effect on our
business, financial condition and results of operations.

      We have only limited manufacturing experience with certain products.

      Although we have manufactured over twelve million diagnostic tests based
on our proprietary applications of ELISA (enzyme linked immuno-absorbent assay)
technology, certain of our diagnostic products in consideration for future
development, incorporate technologies with which we have little manufacturing
experience. Assuming successful development and receipt of required regulatory
approvals, significant work may be required to scale up production for each new
product prior to such product's commercialization. There can be no assurance
that such work can be completed in a timely manner and that such new products
can be manufactured cost-effectively, to regulatory standards or in sufficient
volume.

      Due to the specialized nature of our business, our success will be highly
      dependent upon our ability to attract and retain qualified scientific and
      executive personnel.

      We believe our success will depend to a significant extent on the efforts
and abilities of Dr. Luis R. Lopez and Douglass T. Simpson, who would be
difficult to replace. There can be no assurance that we will be successful in
attracting and retaining such skilled personnel, who are generally in high
demand by other companies. The loss of, inability to attract, or poor
performance by key scientific and executive personnel may have a material
adverse effect on our business, financial condition and results of operations.

      The testing, manufacturing and marketing of medical diagnostic devices
      entails an inherent risk of product liability claims.

      To date, we have experienced no product liability claims, but any such
claims arising in the future could have a material adverse effect on our
business, financial condition and results of operations. Potential product
liability claims may exceed the amount of our insurance coverage or may be
excluded from coverage under the terms of our policy or limited by other claims
under our umbrella insurance policy. Additionally, there can be no assurance
that our existing insurance can be renewed by us at a cost and level of coverage
comparable to that presently in effect, if at all. In the event that we are held
liable for a claim against which we are not insured or for damages exceeding the
limits of our insurance coverage, such claim could have a material adverse
effect on our business, financial condition and results of operations.

      There has, to date, been no active public market for our Common Stock, and
      there can be no assurance that an active public market will develop or be
      sustained.

      Although our Common Stock has been traded on the OTC Bulletin Board(R)
since February 1998, the trading has been sporadic with insignificant volume.

      Moreover, the over-the-counter markets for securities of very small
companies historically have experienced extreme price and volume fluctuations.
These broad market fluctuations and other factors, such as new product
developments, trends in our industry, the investment markets, economic
conditions generally, and quarterly variation in our results of operations, may
adversely affect the market price of our common stock. In addition, our common
stock is subject to rules adopted by the Securities and Exchange Commission
regulating broker-dealer practices in connection with transactions in "penny
stocks." As a result, many brokers are unwilling to engage in transactions in
our Common Stock because of the added disclosure requirements.

      There are risks associated with fluctuating exchange rates.

      Our financial statements are presented in US dollars. At the end of each
fiscal quarter and the fiscal year, we convert the financial statements of
Corgenix UK, which operates in pounds sterling, into US dollars, and consolidate
them with results from Corgenix, Inc. We may, from time to time, also need to
exchange currency from income generated by Corgenix UK. Foreign exchange rates
are volatile and can change in an unknown and unpredictable fashion. Should the
foreign exchange rates change to levels different than anticipated by us, our
business, financial condition and results of operations may be materially
adversely affected.




<PAGE>





                          CORGENIX MEDICAL CORPORATION


                                     Part II


                                Other Information


Item 1.    Legal Proceedings


      Corgenix is not a party to any material litigation or legal proceedings.


Item 2.    Changes in Securities and Use of Proceeds


       None

Item 3.    Defaults Upon Senior Securities


           The variable note payable to a bank was due in full at January 31,
      2005. The Company has not repaid the loan and has informed the Bank of the
      status of its current institutional financing. No demand for repayment has
      been made. It is the intention of the Company to pay the note in full with
      the proceeds from the current institutional financing, or alternatively to
      attempt to convert this loan to a term loan with a due date of three to
      five years. There is no assurance that the current institutional financing
      will be successful or, in the alternative, that the bank will agree to
      such terms in which case a near-term infusion of capital will be necessary
      to satisfy this note. Since the Company needs additional financing to meet
      our debt requirements, there is no assurance that we will be able to
      obtain such financing on terms satisfactory to us, if at all. The effects
      on the financial statements of not obtaining suitable financing cannot be
      determined.



Item 4.    Submission of Matters to a Vote of Security Holders


      None

Item 5.    Other Information


      None

Item 6.  Exhibits and Reports on Form 8-K.

a. Index to and Description of Exhibits



Exhibit
Number   Description of Exhibit

2.1      Agreement and Plan of Merger dated as of March 12, 2004 by
         and among Genesis Bioventures, Inc., GBI Acquisition
         Corporation and Corgenix Medical Corporation.
2.2      Amended and Restated Agreement and Plan of Merger as of
         May 21, 2004 by and among Genesis Bioventures, Inc., GBI
         Acquisition Corporation and Corgenix Medical Corporation.
2.3      Amendment No. 1 to Amended and Restated Agreement and Plan
         of Merger as of October 15, 2004 by and among Genesis
         Bioventures, Inc., GBI Acquisition Corporation and
         Corgenix Medical Corporation.
2.4      Amendment No. 2 to Amended and Restated Agreement and Plan
         of Merger as of November 30, 2004 by and among Genesis
         Bioventures, Inc., GBI Acquisition Corporation and
         Corgenix Medical Corporation.
2.5      Amendment No. 3 to Amended and Restated Agreement and Plan
         of Merger as of December 9, 2004 by and among Genesis
         Bioventures, Inc., GBI Acquisition Corporation and
         Corgenix Medical Corporation.
2.6      Amendment No. 4 to Amended and Restated Agreement and Plan
         of Merger as of December 31, 2004 by and among Genesis
         Bioventures, Inc., GBI Acquisition Corporation and
         Corgenix Medical Corporation.
3.1      Articles of Incorporation, as amended, filed with the Company's
         Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference.
3.2      Bylaws, filed with the Company's Registration Statement on Form 10-SB
         filed June 29, 1998, and incorporated herein by reference.

10.4     License Agreement dated June 30, 2001 between Chugai
         Diagnostic Science Co., Ltd. and Corgenix Medical
         Corporation, filed with the Company's Form 10-KSB, and
         incorporated herein by reference.

10.5     Office Lease dated May 5, 2001 between Crossroads West
         LLC/Decook Metrotech LLC and Corgenix, Inc., filed with
         the Company's Form-10KSB, and incorporated herein by
         reference.
10.6     Guarantee dated November 1, 1997 between William George Fleming,
         Douglass Simpson and Geoffrey Vernon Callen, filed with the Company's
         Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference.
10.7     Employment Agreement dated April 1, 2001 between Luis R. Lopez and the
         Company, filed with the Company's Form 10-KSB, and incorporated herein
         by reference.

10.8     Employment Agreement dated April 1, 2001 between Douglass T. Simpson
         and the Company, filed with the Company's Form 10-KSB, and incorporated
         herein by reference.
10.9     Employment Agreement dated April 1, 2001 between Ann L. Steinbarger and
         the Company, filed with the Company's Form 10-KSB, and incorporated
         herein by reference.
10.10    Employment Agreement dated April 1, 2001 between Taryn G. Reynolds and
         the Company, filed with the Company's Form 10-KSB, and incorporated
         herein by reference.
10.11    Employment Agreement dated April 1, 2001 between Catherine (O'Sullivan)
         Fink and the Company, filed with the Company's Form 10-KSB, and
         incorporated herein by reference.
10.14    Note dated January 6, 1997 between REAADS Medical Products, Inc. and
         Eagle Bank, filed with the Company's Registration Statement on Form
         10-SB filed June 29, 1998, and incorporated herein by reference.
10.15    Form of Indemnification Agreement between the Company and its directors
         and officers, filed with the Company's Registration Statement on Form
         10-SB/A-1 filed September 24, 1998 and incorporated herein by
         reference.
10.16    Warrant agreement dated June 1, 2000 between the Company and Taryn G.
         Reynolds, filed with the Company's Form 10-KSB, and incorporated herein
         by reference.
10.17    Employment Agreement dated March 1, 2001 between William H. Critchfield
         and the Company, filed with the Company's filing on Form 10-QSB for the
         fiscal quarter ended March 31, 2001.
10.19    Consulting Agreement dated September 29, 2002 between Eiji Matsuura,
         Ph.D and the Company, filed with the Company's Form 10-QSB, and
         incorporated herein by reference.
10.20    License Agreement dated September 29, 2002 between Eiji Matsuura, Ph.D
         and the Company, filed with the Company's Form 10-QSB, and incorporated
         herein by reference.
10.23    Amended and Restated 1999 Incentive Stock Plan filed with the Company's
         filing of Proxy Statement Schedule 14A Information, and incorporated
         herein by reference.
10.24    Amended and Restated Employee Stock Purchase Plan, filed with the
         Company's filing of Proxy Statement Schedule 14A Information, and
         incorporated herein by reference.
10.28    Warrant Agreement dated October 11, 2001, between Phillips V. Bradford
         and the Company, filed with the Company's Form 10-QSB, and incorporated
         herein by reference.
10.29    Warrant Agreement dated October 11, 2001 between Charles F. Ferris and
         the Company, filed with the Company's Form 10-QSB, and incorporated
         herein by reference.
10.30    Underlease Agreement dated October 3, 2001 between G.V. Calen, A.G.
         Pirmohamed and Corgenix UK, Ltd,. filed with the Company's Form 10-QSB,
         and incorporated herein by reference.
10.31    Distribution Agreement and OEM Agreement dated March 14, 2002 between
         RhiGene, Inc., and the Company, filed with the Company's Form 10-QSB,
         and incorporated herein by reference.
10.32    License Agreement dated October 19, 2004 between McMaster
         University, Creative Clinical Concepts, Inc., and the
         Company.
21.1     Subsidiaries of the Registrant, filed as Exhibit 21.1 to the Company's
         Registration Statement on Form 10-SB, filed June 29, 1998.
31.1*    Certification pursuant to section 302 of the
         Sarbanes-Oxley Act of 2002.
31.2*    Certification pursuant to section 302 of the
         Sarbanes-Oxley Act of 2002
32.1*    Certification by Chief Executive Officer pursuant to 18 U.S.C. Section
         1350, or adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
         2002.
32.2*    Certification by Principal Financial Officer pursuant to 18 U.S.C.
         Section 1350, or adopted pursuant to Section 906 of the Sarbanes-Oxley
         Act of 2002.
* Filed Herewith
---------------------------------------
      (b)  Reports on Form 8-K.

1. Form 8-K filed March 14, 2005 Changes in Accountant

2. Form 8-K/A filed March 22, 2005 Changes in Accountant

3. Form 8-K/A filed April 13, 2005 Changes in Accountant


<page>
                                                                    Exhibit 31.1
                                 CERTIFICATIONS

I, Douglass T. Simpson, Chief Executive Officer and President, certify that:

   1. I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
   Corporation.

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.         Based on my knowledge, the financial statements, and other financial
           information included in this report, fairly present in all material
           respects the financial condition, results of operations and cash
           flows of the registrant as of, and for, the periods presented in this
           quarterly report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           for the small business issuer and have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this quarterly report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of an annual
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.

Date:  May 11, 2005


/S/Douglass T. Simpson
Chief Executive Officer and President

<page>
                                                                 Exhibit 31.2
                                 CERTIFICATIONS



I, William H. Critchfield, Chief Financial Officer, certify that:

   1. I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
      Corporation.

   2. Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this quarterly
      report;

4.         The small business issuer's other certifying officers and I are
           responsible for establishing and maintaining disclosure controls and
           procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
           for the small business issuer and have:

a.         Designed such disclosure controls and procedures, or caused such
           disclosure controls and procedures to be designed under our
           supervision, to ensure that material information relating to the
           small business issuer, including its consolidated subsidiaries, is
           made known to us by others within those entities, particularly during
           the period in which this quarterly report is being prepared;
b.         Evaluated the effectiveness of the small business issuer's disclosure
           controls and procedures and presented in this report our conclusions
           about the effectiveness of the disclosure controls and procedures, as
           of the end of the period covered by this report based on such
           evaluation; and
c.         Disclosed in this report any change in the small business issuer's
           internal control over financial reporting that occurred during the
           small business issuer's most recent fiscal quarter (the small
           business issuer's fourth fiscal quarter in the case of an annual
           report) that has materially affected, or is reasonably likely to
           materially affect, the small business issuer's internal control over
           financial reporting; and

5.         The small business issuer's other certifying officers and I have
           disclosed, based on our most recent evaluation of internal control
           over financial reporting, to the small business issuer's auditors and
           the audit committee of registrant's board of directors:

a.         All significant deficiencies in the design or operation of internal
           control over financial reporting which are reasonably likely to
           adversely affect the small business issuer's ability to record,
           process, summarize and report financial information; and
b.         Any fraud, whether or not material, that involves management or other
           employees who have a significant role in the small business issuer's
           internal control over financial reporting.

Date:  May 11, 2005


/S/William H. Critchfield
Chief Financial Officer

<page>
                                                                 Exhibit 32.1


                                  CERTIFICATION
             PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
        SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
                              UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of section 1350, chapter 63 of Title 18, United States Code), I Douglass T.
Simpson, Chief Executive Officer and President of Corgenix Medical Corporation,
a Nevada corporation (the "Company"), does hereby certify with respect to the
Quarterly Report of the Company on Form 10-QSB for the quarter ended September
30, 2004 as filed with the Securities an Exchange Commission (the "10-QSB
Report") that:

               (i) the 10-QSB Report fully complies with the requirements of
                 section 13(a) or 15(d) of the Securities Exchange Act of 1934;
                 and

               (ii) the information contained in the 10-QSB Report fairly
                 presents, in all material respects, the financial condition and
                 results of operations of the Company.


           Dated:    May 11, 2005





           This Certification is made solely for purposes of 18 U.S.C. Section
           1350, subject to the knowledge standard contained therein, and not
           for any other purpose.

           A signed original of this written statement required by Section 906
           of the Sarbanes-Oxley Act has been provided to the Company and will
           be retained by the Company and furnished to the Securities and
           Exchange Commission or its staff request. This written statement
           shall not be deemed to be "filed" as part of the quarterly report on
           Form 10-QSB that it accompanies.


/S/ Douglass T. Simpson
 Chief Executive Officer and President
<page>
                                                                Exhibit 32.2


                                  CERTIFICATION
             PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
          SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
                                 UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of section 1350, chapter 63 of Title 18, United States Code), I William H.
Critchfield, Chief Financial Officer of Corgenix Medical Corporation, a Nevada
corporation (the "Company"), does hereby certify with respect to the Quarterly
Report of the Company on Form 10-QSB for the quarter ended September 30, 2004 as
filed with the Securities an Exchange Commission (the "10-QSB Report") that:

(i)              the 10-QSB Report fully complies with the requirements of
                 section 13(a) or 15(d) of the Securities Exchange Act of 1934;
                 and

               (ii) the information contained in the 10-QSB Report fairly
                 presents, in all material respects, the financial condition and
                 results of operations of the Company.


           Dated:    May 11, 2005





           This Certification is made solely for purposes of 18 U.S.C. Section
           1350, subject to the knowledge standard contained therein, and not
           for any other purpose.

           A signed original of this written statement required by Section 906
           of the Sarbanes-Oxley Act has been provided to the Company and will
           be retained by the Company and furnished to the Securities and
           Exchange Commission or its staff request. This written statement
           shall not be deemed to be "filed" as part of the quarterly report on
           Form 10-QSB that it accompanies.


/S/ William H. Critchfield
Chief  Financial Officer

<page>
                                   SIGNATURES


      In accordance with the requirements of the Securities Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                    CORGENIX MEDICAL CORPORATION



May 11, 2005                     By:/s/ Douglass T. Simpson
                                    Douglass T. Simpson
                                    Chief Executive Officer and President